Oxidative post-translational modifications of α-synuclein in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease

被引:158
作者
Przedborski, S
Chen, QP
Vila, M
Giasson, BI
Djaldatti, R
Vukosavic, S
Souza, JM
Jackson-Lewis, V
Lee, VMY
Ischiropoulos, H
机构
[1] Columbia Univ, Dept Neurol, Neurosci Res Movement Disorder Div, New York, NY 10032 USA
[2] Columbia Univ, Dept Pathol, New York, NY 10032 USA
[3] Childrens Hosp Philadelphia, Stokes Res Inst, Philadelphia, PA 19104 USA
[4] Childrens Hosp Philadelphia, Dept Biochem & Biophys, Philadelphia, PA 19104 USA
[5] Univ Penn, Ctr Neurodegenerat Dis Res, Philadelphia, PA 19104 USA
[6] Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA
关键词
dopaminergic neurons; MPTP; neurodegeneration; Parkinson's disease; substantia nigra; synuclein;
D O I
10.1046/j.1471-4159.2001.00174.x
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Structural and functional alterations of alpha -synuclein is a presumed culprit in the demise of dopaminergic neurons in Parkinson's disease (PD), alpha -Synuclein mutations are found in familial but not in sporadic PD, raising the hypothesis that effects similar to those of familial PD-linked alpha -synuclein mutations may be achieved by oxidative post-translational modifications. Here, we show that wild-type alpha -synuclein is a selective target for nitration following peroxynitrite exposure of stably transfected HEK293 cells. Nitration of alpha -synuclein also occurs in the mouse striatum and Ventral midbrain following administration of the parkinsonian neurotoxin 1-methyt-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Conversely, beta -synuclein and synaptophysin were not nitrated in MPTP-intoxicated mice. Our data demonstrate that alpha -synuclein is a target for tyrosine nitration, which, by disrupting its biophysical properties, may be relevant to the putative role of alpha -synuclein in the neurodegeneration associated with MPTP toxicity and with PD.
引用
收藏
页码:637 / 640
页数:4
相关论文
共 50 条
  • [31] Metallobiology of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity
    Hare, Dominic J.
    Adlard, Paul A.
    Doble, Philip A.
    Finkelstein, David I.
    METALLOMICS, 2013, 5 (02) : 91 - 109
  • [32] Neurochemical evidence for agmatine modulation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxicity
    Gilad, GM
    Gilad, VH
    Finberg, JPM
    Rabey, JM
    NEUROCHEMICAL RESEARCH, 2005, 30 (6-7) : 713 - 719
  • [33] Increasing levels of the endocannabinoid 2-AG is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease
    Mounsey, Ross B.
    Mustafa, Sarah
    Robinson, Lianne
    Ross, Ruth A.
    Riedel, Gernot
    Pertwee, Roger G.
    Teismann, Peter
    EXPERIMENTAL NEUROLOGY, 2015, 273 : 36 - 44
  • [34] A Mouse Model of 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine (MPTP)-Induced Parkinson Disease Shows that 2-Aminoquinoline Targets JNK Phosphorylation
    Zhu, Meie
    Gong, Daokai
    MEDICAL SCIENCE MONITOR, 2020, 26
  • [35] The Intranasal Administration of 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine (MPTP): A New Rodent Model to Test Palliative and Neuroprotective Agents for Parkinson's disease
    Prediger, Rui D. S.
    Aguiar, Aderbal S., Jr.
    Moreira, Eduardo L. G.
    Matheus, Filipe C.
    Castro, Adalberto A.
    Walz, Roger
    De Bem, Andreza F.
    Latini, Alexandra
    Tasca, Carla I.
    Farina, Marcelo
    Raisman-Vozari, Rita
    CURRENT PHARMACEUTICAL DESIGN, 2011, 17 (05) : 489 - 507
  • [36] PROTECTIVE EFFECTS OF VALPROIC ACID ON THE NIGROSTRIATAL DOPAMINE SYSTEM IN A 1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE MOUSE MODEL OF PARKINSON'S DISEASE
    Kidd, S. K.
    Schneider, J. S.
    NEUROSCIENCE, 2011, 194 : 189 - 194
  • [37] Involvement of calcium in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced experimental parkinsonism
    Samantaray, S
    Mohanakumar, KP
    JOURNAL OF NEUROCHEMISTRY, 2003, 87 : 106 - 106
  • [38] Neurochemical Evidence for Agmatine Modulation of 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine (MPTP) Neurotoxicity
    Gad M. Gilad
    Varda H. Gilad
    John P. M. Finberg
    Jose M. Rabey
    Neurochemical Research, 2005, 30 : 713 - 719
  • [39] Biochemical and immunohistological changes in the brain of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated mouse
    Araki, T
    Mikami, T
    Tanji, H
    Matsubara, M
    Imai, Y
    Mizugaki, M
    Itoyama, Y
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2001, 12 (03) : 231 - 238
  • [40] Evaluation of Nigrostriatal Neurodegeneration and Neuroinflammation Following Repeated Intranasal 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine (MPTP) Administration in Mice, an Experimental Model of Parkinson’s Disease
    Fabrine S. M. Tristão
    Majid Amar
    Ines Latrous
    Elaine A. Del-Bel
    Rui D. Prediger
    Rita Raisman-Vozari
    Neurotoxicity Research, 2014, 25 : 24 - 32